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Retrospective comparison of the incidence of acute kidney injury in patients
treated with intravenous polymyxin B or intravenous colistimethate sodium
Rebecca A. Sumner, Pharm.D.; Jarrod Kile, RPh, BCPS
Lehigh Valley Health Network, Allentown, Pennsylvania

Purpose

Study Population

Disclosure

This study will evaluate and compare the incidence of acute kidney injury
among patients treated with intravenous polymyxin B and intravenous
colistimethate sodium. In a secondary analysis, risk factors that may
contribute to the development of acute kidney injury in each group will be
evaluated.

•	Inclusion Criteria:

Authors of the presentation have the following to disclose concerning
possible financial or personal relationships with commercial entities that may
have a direct or indirect interest in the subject matter of this presentation.

Background

		 −	Diagnosis of end-stage renal disease or a dialysis candidate prior
to therapy initiation, known hypersensitivity to polymyxin B or
colistimethate sodium, less than 48 hours of polymyxin therapy, previous
exposure to polymyxin therapy at any point during the specified study
period and use of inhalational colistimethate sodium monotherapy.

•	The polymyxin drug class is effective against Gram-negative bacteria
including Pseudomonas aeruginosa, Acinetobacter baumannii and
Klebsiella pneumoniae.
•	The polymyxins as antimicrobial therapy had previously been replaced by
more effective, less toxic agents. The emergence of multidrug-resistant
1
bacterium has prompted their utilization in clinical practice.
•	Colistin is available in two forms, the pro-drug colistimethate sodium and
its active, more toxic form, colistin sulfate. Conversion of colistimethate
sodium to colistin is required for antimicrobial activity since colistimethate
sodium itself is inactive. Colistimethate sodium is the only formulation
currently available in the United States.2
•	The Risk, Injury, Failure, Loss, End-Stage (RIFLE) criterion defines three
severity grades for acute kidney injury (risk, injury, failure) and two
outcomes (loss and end-stage). Grading of renal dysfunction is classified
3
by a change in serum creatinine or glomerular filtration rate.
•	The incidence of acute kidney injury with colistimethate sodium is variable,
4
ranging from 0%-37%. Recent studies utilizing the RIFLE criteria report
5,6,7
incidences as high as 31%-53.5%.
•	The incidence of acute kidney injury associated with polymyxin B ranges
4
widely from 6%-54%. A recent study reported an incidence of 60%
8
through utilization of the RIFLE criteria.
•	Risk factors for the development of kidney injury with polymyxin
therapy may include treatment duration greater than 14 days, higher
total cumulative drug exposure, use of concomitant nephrotoxic agents
and presence of co-morbidities including chronic kidney diseae and
hypertension.

Study Design
Retrospective chart review of 150 patients in each group receiving
intravenous polymyxin B or intravenous colistimethate sodium for at least 48
hours for all Gram-negative bacterial infections.

		 −	Patients over 18 years of age administered either agent during the
course of hospital stay for any type of Gram-negative infection.

•	Exclusion Criteria:

Methods
•	The primary outcome is to compare the incidence of acute kidney
injury in patients administered intravenous polymyxin B to patients
administered intravenous colistimethate sodium.
		 −	Acute kidney injury will be defined by use of the RIFLE criteria
measured by change in serum creatinine.

•	A secondary analysis will be performed based on patient
demographics in each group to evaluate risk factors that may be
predictors in the development of acute kidney injury.
•	Patient data to be collected will include:
−	Age, weight at therapy initiation, gender, APACHE II score and comorbid disease states (chronic kidney disease, diabetes mellitus,
hypertension).
MDPV
		 −	Baseline and serial serum creatinine, actual body weight-based daily
dose, cumulative dose and duration of treatment.
		 −	Use and duration of concomitant nephrotoxic agents (vancomycin,
aminoglycosides, vasopressors, amphotericin B, angiotensin
converting enzyme inhibitors, angiotensin receptor blockers,
calcineurin inhibitors, non-steroidal anti-inflammatory drugs,
ganciclovir, IV contrast medium).

•	Following data collection, the rate of acute kidney injury in each
group will be determined and compared for significance utilizing the
chi-squared test.

• Rebecca Sumner-Nothing to disclose
•	Jarrod Kile- Nothing to disclose
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